Payment overview · 2025
General Payments
$7,180.56
296 reported records · 22 companies
Healthcare provider profile · identity verified
Cindy Chen, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Clinical Nurse Specialist|Psychiatric/Mental Health · ORANGE, CA · NPI 1023756053
Verified facts
What the public records show
CMS Open Payments records show Cindy Chen, PA-C received $7,180.56 in general payments during 2025 across 296 reported records.
Neurocrine BioSciences, Inc. accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $1,059.59 | 14.8% | 30 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $866.28 | 12.1% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $718.23 | 10.0% | 43 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $679.24 | 9.5% | 23 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $644.77 | 9.0% | 29 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $638.72 | 8.9% | 23 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $573.63 | 8.0% | 22 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $497.40 | 6.9% | 24 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $295.16 | 4.1% | 15 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $213.05 | 3.0% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $212.12 | 3.0% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $171.09 | 2.4% | 14 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $146.29 | 2.0% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $140.11 | 1.9% | 6 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $87.01 | 1.2% | 4 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $84.90 | 1.2% | 3 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $59.52 | 0.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.79 | 0.4% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.91 | 0.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.65 | 0.2% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $14.41 | 0.2% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $10.69 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,058.92 | 294 |
| Education | $121.64 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $1,059.59 | 30 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $748.63 | 35 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $718.23 | 43 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $666.21 | 16 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $638.72 | 23 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $544.90 | 21 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $497.40 | 24 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $454.29 | 21 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $446.52 | 17 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $213.05 | 12 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $212.12 | 7 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $200.07 | 6 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $200.07 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $191.30 | 9 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $182.89 | 8 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $171.09 | 14 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $146.29 | 10 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $140.11 | 6 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $123.23 | 5 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $87.01 | 4 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $84.90 | 3 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $59.52 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $10.69 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 107 | 43 |
| Alprazolam | Alprazolam | 98 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 97 | 41 |
| Metformin Hcl | Metformin Hcl | 95 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 92 | 40 |
| Losartan Potassium | Losartan Potassium | 83 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 27 |
| Lisinopril | Lisinopril | 69 | 39 |
| Naproxen | Naproxen | 66 | 27 |
| Ibuprofen | Ibuprofen | 65 | 27 |
| Omeprazole | Omeprazole | 65 | 33 |
| Azithromycin | Azithromycin | 62 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 14 |
| Furosemide | Furosemide | 44 | 27 |
| Carvedilol | Carvedilol | 42 | 17 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 19 |
| Trazodone Hcl | Trazodone Hcl | 37 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 19 |
| Meclizine Hcl | Meclizine Hcl | 35 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 17 |
| Baclofen | Baclofen | 32 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 16 |
| Gabapentin | Gabapentin | 32 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 13 |
| Potassium Chloride | Potassium Chloride | 31 | 21 |
| Tramadol Hcl | Tramadol Hcl | 31 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Benazepril Hcl | Benazepril Hcl | 25 | 11 |
| Ozempic | Semaglutide | 25 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Famotidine | Famotidine | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Zanaflex | Tizanidine Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,180.56 · 296 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, Azstarys, BRIXADI, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, Jornay PM, LYBALVI, Onyda XR, Quviviq, REXULTI, SPRAVATO, SUBLOCADE, TRINTELLIX, UZEDY, VRAYLAR, Xelstrym, ZEPBOUND, ZURZUVAE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error